S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
CVE:ZOM

Zomedica Pharmaceuticals Stock Forecast, Price & News

C$0.28
-0.02 (-6.56 %)
(As of 02/5/2020)
Add
Compare
Today's Range
C$0.29
Now: C$0.29
C$0.29
50-Day Range
C$0.29
MA: C$0.29
C$0.29
52-Week Range
C$0.29
Now: C$0.29
C$0.52
Volume4,800 shs
Average Volume2,858 shs
Market CapitalizationC$36.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone734-369-2555
Employees27

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.05 per share
Book ValueC$0.05 per share

Profitability

Miscellaneous

Market CapC$36.73 million
Next Earnings DateN/A
OptionableNot Optionable
C$0.28
-0.02 (-6.56 %)
(As of 02/5/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zomedica Pharmaceuticals (CVE:ZOM) Frequently Asked Questions

Who are some of Zomedica Pharmaceuticals' key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals investors own include Heat Biologics (HTBX), Biocept (BIOC), Remark (MARK), Onconova Therapeutics (ONTX), Vislink Technologies (VISL), Genius Brands International (GNUS), Ritter Pharmaceuticals (RTTR), T2 Biosystems (TTOO), Guardion Health Sciences (GHSI) and MicroVision (MVIS).

Who are Zomedica Pharmaceuticals' key executives?

Zomedica Pharmaceuticals' management team includes the following people:
  • Mr. Gerald L. Solensky Jr., Chairman, Pres & CEO (Age 45)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 52)
  • Dr. Stephanie Morley D.V.M., DVM, COO & VP of Product Devel. (Age 44)
  • Mr. Michael Schilk, VP of Sales
  • Mr. David Eaton, VP of Marketing

What is Zomedica Pharmaceuticals' stock symbol?

Zomedica Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."

How do I buy shares of Zomedica Pharmaceuticals?

Shares of ZOM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Zomedica Pharmaceuticals' stock price today?

One share of ZOM stock can currently be purchased for approximately C$0.29.

How big of a company is Zomedica Pharmaceuticals?

Zomedica Pharmaceuticals has a market capitalization of C$36.73 million. Zomedica Pharmaceuticals employs 27 workers across the globe.

What is Zomedica Pharmaceuticals' official website?

The official website for Zomedica Pharmaceuticals is www.zomedica.com.

How can I contact Zomedica Pharmaceuticals?

The company can be reached via phone at 734-369-2555.

This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.